Clinical Trial Update: Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy

View source ↗

Summary

A completed post-authorization safety study in North America evaluating pregnancy and infant outcomes after dupilumab exposure during pregnancy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Atopic Dermatitis

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Atopic Dermatitis (AD), Asthma | Status: COMPLETED